The metabolites analysis of tumor patients after HF1K16 treatment based on LC-MS/MS technology

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200059761

Enrollment

Unknown

Registered

2022-05-11

Start date

2022-05-03

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Formally enrolled subjects in the HF1K16-101 clinical trial, and participate in HF1K16 multi-dose administration treatment; 2. Informed consent is willing to participate in this research subjects.

Exclusion criteria

Exclusion criteria: 1. Subjects who cannot collect blood or collect urine and stool samples according to the regulations; 2. Other circumstances that the researcher considers inappropriate to participate in this study.

Design outcomes

Primary

Measure	Time frame
Analysis of the changes of metabolites (amino acids, organic acids, fatty acids, reducing sugars, bile acids and more than 300 metabolites) in vivo after HF1K16 treatment;	—

Countries

China

Contacts

Public ContactJian Liu

The First Affliated Hospital, Zhejiang University School of Medicine

lindaliu87@zju.edu.cn+86 13958054006

Outcome results